Full-Time
Posted on 9/4/2025
Venture funding for AI and healthtech
$175k - $195k/yr
Mountain View, CA, USA
Hybrid
| , |
Samsung Next funds and supports bold founders building transformative technologies in AI, intelligent machines, healthtech, consumer services, and frontier tech. It operates as Samsung’s corporate venture arm, providing capital, mentorship, and hands-on support to help startups scale, with access to Samsung’s resources, customers, and global network. The product is not a consumer app but a service for startups: funding combined with operational help, go-to-market support, and strategic partnerships that leverage Samsung’s platforms. The company differentiates itself through its tight integration with a global hardware and consumer electronics giant, enabling portfolio companies to pilot, validate, and deploy at scale within Samsung’s ecosystem. Its goal is to identify and back ambitious founders whose technologies can transform industries and eventually reach widespread adoption through Samsung’s reach and infrastructure.
Company Size
201-500
Company Stage
N/A
Total Funding
$6.4B
Headquarters
Mountain View, California
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Flexible Work Hours
Beacon Biosignals has extended its Series B financing to $97 million, bringing total funding to over $132 million. The upsized round includes new investors JSL Health, Palo Santo VC, Kicker Ventures and Samsung Next. The Boston-based company combines FDA-cleared wearable EEG technology with AI to capture and analyse brain data for neurology, psychiatry and sleep medicine applications. The additional capital will accelerate Beacon's development of at-home EEG and advanced analytics for diagnostics, clinical trials and precision medicine. The original $86 million Series B was led by healthcare and technology investors including Innoviva, GV, S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures. The platform provides clinicians and biopharma partners with objective measures of brain function.
Xona, building the next era of global positioning, navigation, and timing (PNT) infrastructure, today announced $170 million Series C funding.
Xona, a commercial space company building positioning, navigation and timing infrastructure, has raised $170 million in an oversubscribed Series C round led by Mohari Ventures Natural Capital. Participants include Craft Ventures, ICONIQ, Woven Capital, NGP Capital, Samsung Next and Hexagon. The company is developing Pulsar, a navigation service broadcast from low Earth orbit satellites with stronger signals and military-grade encryption, compatible with existing GPS devices. Over a dozen commercial receiver partners are tracking Pulsar signals, with early customers expected to benefit from coverage by 2027. The funding will accelerate constellation deployment and manufacturing scale-up at Xona's new Burlingame, California factory. At full production, the company aims to manufacture more navigation satellites weekly than the US currently produces annually, deploying its 258-satellite constellation within a few years.
Island startup Grid Beyond lands Samsung investment for grid-balancing software
Nucleus Genomics, a clinical-grade whole-genome sequencing platform, has received a strategic investment from Samsung Next, following a $14 million Series A led by Founders Fund and Seven Seven Six. The company offers a $499 physician-ordered test sequencing approximately 100% of a patient's DNA, covering over 2,000 diseases through a CLIA-certified, CAP-accredited US lab. Nucleus recently acquired Cambrean, an AI-powered wearable health platform, to combine continuous biometric data with genetic baselines. Samsung Next cited the company's scientific rigour and potential as a genetic baseline layer for wearables and health sensors. The company initially drew attention with its Nucleus Embryo product, allowing IVF patients to compare embryos based on traits including appearance and cognitive ability. Nucleus now appears to be repositioning as a broader preventive health genomics platform.